SCHEMBL8279784

SCHEMBL8279784

NC(Cc1cccc(Cl)c1)C1CCN(C(=O)C2CC2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.50
ALDH1A1 P00352 3/20 0.47
ALDH1A2 O94788 1/20 0.47
ALDH2 P05091 1/20 0.47
ALDH3A1 P30838 1/20 0.47
ALDH1A3 P47895 1/20 0.47
DPP4 P27487 2/20 0.46
DPP7 Q9UHL4 2/20 0.46
DPP8 Q6V1X1 1/20 0.46
DPP9 Q86TI2 1/20 0.46
TP53 P04637 1/20 0.45
F2 P00734 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HDAC8 Q9BY41 1/20 0.43
PNMT P11086 1/20 0.43
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
EPHX2 P34913 1/20 0.42
CNR1 P21554 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14355373 0.88 ADRB2 (0.45) ADRB2ALDH1A1ALDH1A2ALDH2ALDH3A1
SCHEMBL8282124 0.86 F2 (0.47) ALDH1A1DPP4DPP7DPP8DPP9
SCHEMBL8279781 0.84 F2 (0.43) DPP4DPP7DPP8DPP9F2
SCHEMBL14355378 0.84 ATM (0.57) ALDH1A1DPP4DPP7DPP8DPP9
SCHEMBL8280943 0.84 CHRM2 (0.54) ADRB2ALDH1A1DPP4MEN1KMT2A
SCHEMBL8282125 0.83 AKR1C3 (0.52) ALDH1A1F2HDAC8CNR1
SCHEMBL8280987 0.82 PKM (0.46) ADRB2ALDH1A1DPP4DPP7DPP8
SCHEMBL14355374 0.82 HDAC8 (0.45) ADRB2ALDH1A1DPP4DPP7DPP8
SCHEMBL5188797 0.82 HDAC8 (0.45) ADRB2ALDH1A1DPP4DPP7DPP8
SCHEMBL5571269 0.82 HDAC8 (0.45) ADRB2ALDH1A1DPP4DPP7DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070265261-A1 Dpp-IV Inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2007-11-15 US disclosed
US-20070265261-A1 Dpp-IV Inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2007-11-15 US disclosed
WO-2005121089-A1 DPP-IV INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265261-A1 Dpp-IV Inhibitors DPP4, DPP3, DPP7 ADRB2 1332/4885ALDH1A1 285/4885ALDH1A2 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.